United States, Feb. 12 -- The U.S. Food and Drug Administration has approved a first-of-its-kind device for the treatment of adult patients with locally advanced pancreatic cancer. Optune Pax, developed by Novocure, is a portable, non-invasive device that delivers alternating electrical fields, known as tumor treating fields (TTFields), to the abdomen. TTFields work by physically disrupting the rapid cell division that is characteristic of cancer cells, while minimizing damage to healthy tissue. The approval reflects the FDA's unwavering commitment to advancing safe and effective medical devices that address chronic diseases and improve the lives of Americans and is also aligned with the FDA's Home as a Health Care Hub Initiative, which foc...